MX2021015888A - Fusión de un anticuerpo que se une a cea y 4-1bbl. - Google Patents
Fusión de un anticuerpo que se une a cea y 4-1bbl.Info
- Publication number
- MX2021015888A MX2021015888A MX2021015888A MX2021015888A MX2021015888A MX 2021015888 A MX2021015888 A MX 2021015888A MX 2021015888 A MX2021015888 A MX 2021015888A MX 2021015888 A MX2021015888 A MX 2021015888A MX 2021015888 A MX2021015888 A MX 2021015888A
- Authority
- MX
- Mexico
- Prior art keywords
- 1bbl
- fusion
- antibody binding
- cea
- binding cea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Abstract
La invención se refiere a nuevos anticuerpos contra CEA humanizados y moléculas de unión al antígeno que contienen el trímero de 4-1BBL que se dirige a CEA que comprenden estos anticuerpos contra CEA, así como su uso en el tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19182505 | 2019-06-26 | ||
PCT/EP2020/067582 WO2020260329A1 (en) | 2019-06-26 | 2020-06-24 | Fusion of an antibody binding cea and 4-1bbl |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015888A true MX2021015888A (es) | 2022-03-22 |
Family
ID=67253655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015888A MX2021015888A (es) | 2019-06-26 | 2020-06-24 | Fusión de un anticuerpo que se une a cea y 4-1bbl. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220267464A1 (es) |
EP (1) | EP3990477A1 (es) |
JP (1) | JP2022538075A (es) |
KR (1) | KR20220025848A (es) |
CN (1) | CN114127123A (es) |
AR (1) | AR119295A1 (es) |
AU (1) | AU2020304813A1 (es) |
BR (1) | BR112021026293A2 (es) |
CA (1) | CA3141378A1 (es) |
IL (1) | IL288597A (es) |
MX (1) | MX2021015888A (es) |
TW (1) | TW202115124A (es) |
WO (1) | WO2020260329A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017384126A1 (en) | 2016-12-20 | 2019-05-02 | F. Hoffmann-La Roche Ag | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
EP3601345A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
AU2019355252A1 (en) | 2018-10-01 | 2021-04-01 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
BR112021012101A2 (pt) | 2018-12-21 | 2021-09-08 | F. Hoffmann-La Roche Ag | Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
EP4340805A1 (en) * | 2021-05-21 | 2024-03-27 | BeiGene Switzerland GmbH | Anti-cea and anti-cd137 multispecific antibodies and methods of use |
CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
JP2024515912A (ja) * | 2022-02-21 | 2024-04-11 | シーティーセルズ、インコーポレイテッド | 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質 |
WO2023158027A1 (en) * | 2022-02-21 | 2023-08-24 | Ctcells, Inc. | A fusion protein comprising an antigen binding domain and a cytokine trimer domain |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1096187A (en) | 1977-04-18 | 1981-02-24 | Souhei Monden | Ornament adapted to be fixed by permanent magnets |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5081235A (en) | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2005003156A1 (en) | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides having binding affinity for her2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
EP1711196A4 (en) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS |
WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
ES2527292T3 (es) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Anticuerpos anti-TGF-beta humanizados |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2006211037B2 (en) | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
EP1976885B1 (en) | 2005-12-21 | 2014-12-03 | Amgen Research (Munich) GmbH | Pharmaceutical antibody compositions with resistance to soluble cea |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
RU2570554C2 (ru) | 2009-08-31 | 2015-12-10 | Роше Гликарт Аг | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью |
PT2603530T (pt) | 2010-08-13 | 2018-01-09 | Roche Glycart Ag | Anticorpos anti-fap e métodos de utilização |
WO2012130831A1 (en) | 2011-03-29 | 2012-10-04 | Roche Glycart Ag | Antibody fc variants |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
MX2017006250A (es) | 2014-11-14 | 2017-11-17 | Hoffmann La Roche | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf. |
EP3554542A1 (en) * | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
AU2017384126A1 (en) * | 2016-12-20 | 2019-05-02 | F. Hoffmann-La Roche Ag | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
CN112424228A (zh) * | 2018-07-04 | 2021-02-26 | 豪夫迈·罗氏有限公司 | 新型双特异性激动性4-1bb抗原结合分子 |
BR112021012101A2 (pt) * | 2018-12-21 | 2021-09-08 | F. Hoffmann-La Roche Ag | Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais |
-
2020
- 2020-06-24 WO PCT/EP2020/067582 patent/WO2020260329A1/en unknown
- 2020-06-24 TW TW109121437A patent/TW202115124A/zh unknown
- 2020-06-24 BR BR112021026293A patent/BR112021026293A2/pt not_active Application Discontinuation
- 2020-06-24 CA CA3141378A patent/CA3141378A1/en active Pending
- 2020-06-24 JP JP2021576252A patent/JP2022538075A/ja active Pending
- 2020-06-24 AU AU2020304813A patent/AU2020304813A1/en active Pending
- 2020-06-24 KR KR1020227002699A patent/KR20220025848A/ko unknown
- 2020-06-24 MX MX2021015888A patent/MX2021015888A/es unknown
- 2020-06-24 CN CN202080047289.6A patent/CN114127123A/zh active Pending
- 2020-06-24 EP EP20733647.0A patent/EP3990477A1/en not_active Withdrawn
- 2020-06-26 AR ARP200101825A patent/AR119295A1/es unknown
-
2021
- 2021-12-01 IL IL288597A patent/IL288597A/en unknown
- 2021-12-17 US US17/644,903 patent/US20220267464A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220267464A1 (en) | 2022-08-25 |
WO2020260329A1 (en) | 2020-12-30 |
TW202115124A (zh) | 2021-04-16 |
JP2022538075A (ja) | 2022-08-31 |
IL288597A (en) | 2022-02-01 |
CN114127123A (zh) | 2022-03-01 |
KR20220025848A (ko) | 2022-03-03 |
AU2020304813A1 (en) | 2022-01-06 |
CA3141378A1 (en) | 2020-12-30 |
EP3990477A1 (en) | 2022-05-04 |
BR112021026293A2 (pt) | 2022-03-03 |
AR119295A1 (es) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
AU2020255712B2 (en) | Anti-PD-L1/VEGF bifunctional antibody and use thereof | |
ZA202006859B (en) | Antibodies specific for gucy2c and uses thereof | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
JOP20160154B1 (ar) | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها | |
CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
TN2019000272A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments. | |
MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
PH12020551689A1 (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
MX2021000392A (es) | Anticuerpos anti-mesotelina. | |
IN2014MN00873A (es) | ||
ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
AU2024202102A1 (en) | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof | |
AU2018449846A8 (en) | An anti-B7-H3 antibody | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
ZA202008095B (en) | Humanized antibodies against psma | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. |